Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy is a condition in which the heart muscle becomes thicker than normal. In most people the thickening is in the wall between the two lower chambers, and it can block the flow of blood out of the heart. Most people with the form that has no other cause have a normal life expectancy, but some develop an abnormal heart rhythm that may be life-threatening and a small number develop heart failure. The risk of sudden death is higher than usual, although it remains uncommon. In the United States the label of the medicine mavacamten gives symptomatic obstructive disease as its indication.
Also called HCM
- Condition
- In this atlas
Overview
Technical summary
MeSH descriptor D002312 (Cardiomyopathy, Hypertrophic). The MeSH scope note describes a form of cardiac muscle disease with left or right ventricular hypertrophy, frequent uneven involvement of the heart septum and normal or reduced left ventricular volume. The MedlinePlus Genetics page describes the nonsyndromic form, which is not explained by another cause and does not affect other parts of the body, so its statements on life expectancy and sudden death may not fit every person with the condition. A 2024 US guideline covers management of the condition; only its abstract was read for this atlas.
Burden
No burden claims are published.
Claims and evidence
Context People with cardiomyopathy, as described in MeSH, MedlinePlus, MedlinePlus Genetics and NHLBI reference pages
- Recipient
- Recipient not specified
- Population
- People with cardiomyopathy in general. The pages are written for the public or as a vocabulary and give no study population. They describe adults and also say that newborns and children can have cardiomyopathy. The MedlinePlus Genetics pages describe the nonsyndromic forms, which are not explained by other causes and do not affect other parts of the body.
- Care setting
- General health information for the public; no care setting is stated
- Geography
- United States (pages of US government agencies); the MeSH vocabulary is international
- Life stage
- Not limited by age. NHLBI says people of any age can have cardiomyopathy, including newborns and children, and names peripartum cardiomyopathy as a form that affects some women around pregnancy.
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (descriptive statement)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
- Included
- None stated
- Excluded
- None stated
The MeSH scope note describes hypertrophic cardiomyopathy as a form of heart muscle disease with thickening of the left or right ventricle, frequent uneven involvement of the heart septum and normal or reduced left ventricular volume. MedlinePlus Genetics describes it, in its nonsyndromic form, as thickening of the heart muscle, most often in the wall between the lower chambers, which can obstruct the flow of blood out of the heart. It says most people with this form have a normal life expectancy, that some develop an abnormal heart rhythm that may be life-threatening, that a small number develop heart failure, and that the risk of sudden death is increased although uncommon.
Applies to Recipient not specified People with cardiomyopathy, as described in MeSH, MedlinePlus, MedlinePlus Genetics and NHLBI reference pages
- Certainty method
- Not assessed
- Limitations
- Vocabulary and patient-education pages from US government sources. The MedlinePlus Genetics page describes the nonsyndromic form, which is not explained by another cause and does not affect other parts of the body, so it may not describe every person with the condition. The pages give no study, no size of risk and no population beyond the general public.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (8)
-
Supports MeSH scope note for descriptor D002312 (Cardiomyopathy, Hypertrophic)
- Locator
- scopeNote.@value
- How it applies
- MeSH scope note of the descriptor Cardiomyopathy, Hypertrophic.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
e2dfd8316c24d06935f24c456e33a57491edce6e41d54c3730008928e88c950e- Reuse basis
- The NLM web policies page (sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. This copy was fetched on 2026-10-30 and may not reflect the most current data. The raw bytes are committed in the atlas repository.
-
Supports Nonsyndromic hypertrophic cardiomyopathy (MedlinePlus Genetics)
- Locator
- Description, para 1, sentence 1
- How it applies
- What the condition is.
- Retrieved
- Source effective date
- 2026-06-16
- Source state
- Current
- Version fingerprint
55387d73362d9a3ae21a7fac384499277ea4183402dcc10dcd9e91c51c89ca45- Reuse basis
- MedlinePlus states that works produced by the federal government are not copyrighted, and lists the summaries on health topic pages and Genetics pages as public domain (the page titled Linking to and Using Content from MedlinePlus, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161). It names the A.D.A.M. encyclopedia, drug monographs and many images as copyrighted; this atlas uses only the page summary text. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
-
Supports Nonsyndromic hypertrophic cardiomyopathy (MedlinePlus Genetics)
- Locator
- Description, para 2, sentence 2
- How it applies
- Where the thickening usually occurs.
- Retrieved
- Source effective date
- 2026-06-16
- Source state
- Current
- Version fingerprint
55387d73362d9a3ae21a7fac384499277ea4183402dcc10dcd9e91c51c89ca45- Reuse basis
- MedlinePlus states that works produced by the federal government are not copyrighted, and lists the summaries on health topic pages and Genetics pages as public domain (the page titled Linking to and Using Content from MedlinePlus, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161). It names the A.D.A.M. encyclopedia, drug monographs and many images as copyrighted; this atlas uses only the page summary text. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
-
Supports Nonsyndromic hypertrophic cardiomyopathy (MedlinePlus Genetics)
- Locator
- Description, para 2, sentence 3
- How it applies
- Obstruction of blood flow.
- Retrieved
- Source effective date
- 2026-06-16
- Source state
- Current
- Version fingerprint
55387d73362d9a3ae21a7fac384499277ea4183402dcc10dcd9e91c51c89ca45- Reuse basis
- MedlinePlus states that works produced by the federal government are not copyrighted, and lists the summaries on health topic pages and Genetics pages as public domain (the page titled Linking to and Using Content from MedlinePlus, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161). It names the A.D.A.M. encyclopedia, drug monographs and many images as copyrighted; this atlas uses only the page summary text. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
-
Supports Nonsyndromic hypertrophic cardiomyopathy (MedlinePlus Genetics)
- Locator
- Description, para 4, sentence 1
- How it applies
- Life expectancy of most people with the nonsyndromic form.
- Retrieved
- Source effective date
- 2026-06-16
- Source state
- Current
- Version fingerprint
55387d73362d9a3ae21a7fac384499277ea4183402dcc10dcd9e91c51c89ca45- Reuse basis
- MedlinePlus states that works produced by the federal government are not copyrighted, and lists the summaries on health topic pages and Genetics pages as public domain (the page titled Linking to and Using Content from MedlinePlus, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161). It names the A.D.A.M. encyclopedia, drug monographs and many images as copyrighted; this atlas uses only the page summary text. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
-
Supports Nonsyndromic hypertrophic cardiomyopathy (MedlinePlus Genetics)
- Locator
- Description, para 4, sentence 2
- How it applies
- Abnormal heart rhythm.
- Retrieved
- Source effective date
- 2026-06-16
- Source state
- Current
- Version fingerprint
55387d73362d9a3ae21a7fac384499277ea4183402dcc10dcd9e91c51c89ca45- Reuse basis
- MedlinePlus states that works produced by the federal government are not copyrighted, and lists the summaries on health topic pages and Genetics pages as public domain (the page titled Linking to and Using Content from MedlinePlus, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161). It names the A.D.A.M. encyclopedia, drug monographs and many images as copyrighted; this atlas uses only the page summary text. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
-
Supports Nonsyndromic hypertrophic cardiomyopathy (MedlinePlus Genetics)
- Locator
- Description, para 4, sentence 3
- How it applies
- Heart failure.
- Retrieved
- Source effective date
- 2026-06-16
- Source state
- Current
- Version fingerprint
55387d73362d9a3ae21a7fac384499277ea4183402dcc10dcd9e91c51c89ca45- Reuse basis
- MedlinePlus states that works produced by the federal government are not copyrighted, and lists the summaries on health topic pages and Genetics pages as public domain (the page titled Linking to and Using Content from MedlinePlus, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161). It names the A.D.A.M. encyclopedia, drug monographs and many images as copyrighted; this atlas uses only the page summary text. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
-
Supports Nonsyndromic hypertrophic cardiomyopathy (MedlinePlus Genetics)
- Locator
- Description, para 4, sentence 4
- How it applies
- Sudden death risk.
- Retrieved
- Source effective date
- 2026-06-16
- Source state
- Current
- Version fingerprint
55387d73362d9a3ae21a7fac384499277ea4183402dcc10dcd9e91c51c89ca45- Reuse basis
- MedlinePlus states that works produced by the federal government are not copyrighted, and lists the summaries on health topic pages and Genetics pages as public domain (the page titled Linking to and Using Content from MedlinePlus, fetched 2026-10-30, sha256 e0fbefd889f779a2537ed84f7649157343e52043a577e2a21ddaf9c416844161). It names the A.D.A.M. encyclopedia, drug monographs and many images as copyrighted; this atlas uses only the page summary text. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact Evaluated for this: Aficamten
Applies to Recipient not specified Adults with symptomatic obstructive hypertrophic cardiomyopathy, as described in the US label of Myqorzo
Population, setting and follow-up
- Adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), as the indications section of the label describes them. The passages read give no other age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of Myqorzo (aficamten tablets; Cytokinetics Inc., application NDA219083; the version dated 2025-12-16 in openFDA) calls the product a cardiac myosin inhibitor. It lists the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy, to improve functional capacity and symptoms, as the indication.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the atlas holds no trial result for it. The label also gives a boxed warning, recorded in a separate claim. Contraindications, other warnings, interactions, the pregnancy, lactation and pediatric sections and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Mavacamten
Applies to Mixed recipients Adults, and in the latest label also pediatric patients who weigh at least 30 kg, who have symptomatic obstructive hypertrophic cardiomyopathy, as described in the US label of Camzyos
Population, setting and follow-up
- People with symptomatic obstructive hypertrophic cardiomyopathy. The openFDA copy of the label (version 8, effective 2025-04-17) names adults with symptomatic New York Heart Association (NYHA) class II-III disease. The DailyMed label (version 9, effective 2026-09-30) names adults and pediatric patients who weigh at least 30 kg.
- Prescription medicine under a restricted program; the label records state the program but not a care setting
- United States (labeling approved by the US Food and Drug Administration)
- Adults in version 8 of the label; adults and pediatric patients who weigh at least 30 kg in version 9. The records give no other age limit.
- Gestational age Not reported
- Postnatal age Not reported
The US Food and Drug Administration lists Camzyos (mavacamten) under new drug application NDA214998. The openFDA record names the applicant as BRISTOL and lists the original submission as approved on 28 April 2022 in the class Type 1 - New Molecular Entity. The copy of the label in the openFDA label record (version 8, effective 17 April 2025) says Camzyos is indicated for adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy, to improve functional capacity and symptoms. The label on DailyMed (version 9, effective 30 September 2026) states the indication for adults, and for pediatric patients who weigh at least 30 kg, who have symptomatic obstructive hypertrophic cardiomyopathy. The openFDA application record lists supplement 13, of class Efficacy, as approved on 30 September 2026, the same date as the DailyMed label.Limitations. An FDA approval is a decision about a medicine, not a finding about how much it helps any person. The two label versions state the indication differently and the openFDA copy is the older one; the atlas gives both and treats the DailyMed text as the latest read. The records do not say what supplement 13 changed, so the link between that supplement and the new wording is an inference from the matching date. The DailyMed label is cite only, so its wording is paraphrased. openFDA says not to rely on its data for decisions about medical care. The atlas gives no dose.
-
Claim, not a settled fact Evaluated for this: Septal reduction therapy (myectomy, alcohol septal ablation)
Applies to Adult Adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy, as the US label of dehydrated alcohol injection (ABLYSINOL) states
Population, setting and follow-up
- Adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy, as the indication statement words it. The statement gives no age bounds.
- Not stated beyond the indication statement
- United States (FDA-approved labeling, NDA207987)
- Adults (the label's word); no age bounds given
The openFDA drug label record for dehydrated alcohol injection (ABLYSINOL, BPI Labs, NDA207987; label effective 5 January 2026) states its indication: to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy. The record's brand name field reads Dehydrated Alcohol, and the label text names ABLYSINOL.Limitations. This claim covers one label (set id 314b1dab-8f4f-49ae-a105-f974842818b8). A search of openFDA labels for the word septal in the indications listed ten records, all for dehydrated alcohol with the same indication wording; the other nine were not read. Only the indication statement is recorded; no dosing, administration, warning or clinical study text is recorded on this page. An FDA approval is a decision about a drug, not a finding about how well it works. openFDA says its data are unvalidated and not to be relied on for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Septal reduction therapy (myectomy, alcohol septal ablation)
Applies to Recipient not specified People with obstructive hypertrophic cardiomyopathy, as a 2022 systematic review of septal reduction therapy describes them
Population, setting and follow-up
- Patients with hypertrophic obstructive cardiomyopathy (the review abbreviates it HOCM) who had septal myectomy or alcohol septal ablation in 20 pooled studies. The abstract describes the condition as medical refractory; the pooled studies' own inclusion criteria were not read.
- Not stated; the pooled studies' settings were not read
- Not stated in the passages read
- Not stated in the passages read
- Gestational age Not reported
- Postnatal age Not reported
The introduction of a 2022 systematic review of ventricular arrhythmias after septal reduction therapy (SRT) says that SRT is indicated in patients who are refractory to medical treatments, and that surgical septal myectomy and alcohol septal ablation are the two most common forms. It says no randomized controlled study compares the two, and that alcohol septal ablation works by inducing an iatrogenic myocardial infarction, unlike the direct resection of the thickened muscle in myectomy.Limitations. Background statements written by the review's authors in its introduction, not the review's results. The review searched to October 2020 and was published in 2022; later evidence, guidelines and the effect of newer medicines were not read. The word indicated is the authors'; no guideline was read for this page.
-
Claim, not a settled fact Evaluated for this: Septal reduction therapy (myectomy, alcohol septal ablation)
Applies to Recipient not specified People with obstructive hypertrophic cardiomyopathy, as a 2022 systematic review of septal reduction therapy describes them
The same review pooled 20 studies with 8025 patients. Its abstract reports that ventricular tachycardia or ventricular fibrillation, including appropriate implantable cardioverter defibrillator intervention, was significantly more frequent in the alcohol septal ablation cohort than in the septal myectomy cohort (10% against 5%). It says the risks of sudden cardiac death were similar in the two procedure groups, but that a higher incidence of sudden cardiac arrest, which included sudden cardiac death and resuscitated sudden cardiac arrest, was observed in the alcohol septal ablation group.Limitations. The pooled studies are cohorts: the introduction says no randomized controlled study compares the two procedures, so the groups may differ in ways the pooling does not remove. The abstract is the authors' summary; the risk ratios, confidence intervals and study-level data were not reproduced or checked here. The review searched to October 2020. The review does not separate the effect of patient selection from the procedure. This is not advice on which procedure to choose.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 32
Record details
- Record id
cardio:hypertrophic-cardiomyopathy- Content hash
d549816b879e18c22f00eeb14a946dbcec40f0d560d9b1e45cc748d1b99818be